Small molecule-based Regenerative Stem cell therapy for Myocardial Infarction: Advanced glycation end products (AGEs) aggravate myocardial function via down regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10), 10/June/2015, 9.43 pm

MiRNA-based therapy for Age-associated dementia and Alzheimer’s disease (AD): MiRNA-214 increases the expression of AGE receptor 1 (AGER1), the longevity-promoting gene Sirtuin-1 and decreases advanced glycation end products (AGEs) via down regulation of its target gene, 10/June/2015, 9.30 pm
June 10, 2015
Molecular therapy for metastatic breast cancer: PAPD5 blocks bone metastasis of mammary cancer via down regulation of its target gene, 11/June/2015, 6.58 am
June 11, 2015
Show all

A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published in the 7 March  2013 issue of Nature  by Prof Dimmler, Boon, and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Small molecule-based Regenerative Stem cell therapy for Myocardial Infarction: Advanced glycation end products (AGEs) aggravate  myocardial function via down regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10)

Significance:

Given that: (1)  cardiovascular disease is the leading cause of death worldwide; (2) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were: (i) due to ischemic heart disease; and (ii) expected to be doubled by 2015; and (3) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars, there is an urgent need to find: (i)  a way to induce regeneration of adult cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iii) a side-effect-free natural product-based drug.

Increased levels of Advanced glycation end products (AGEs) has been shown to promote: (1) Reactive oxygen species; (2) Inflammation; (3) insulin resistance; (4) pre-mature ageing features; and (5) cardiovascular diseases.   AGEs, by increasing the expression of their target gene, they may decrease the expression of PNUTS/PPP1R10Thereby, they may: (1) promote DNA damage responses, (2) promote telomere shortening; and (3) inhibit cardimyocyte survival/regeneration.  Thus, pharmacological formulations encompassing Advanced glycation end product inhibitors”may be used to prevent myocardial infarction.

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, Small molecule-based Regenerative Stem cell therapy for Myocardial Infarction: Advanced glycation end products (AGEs) aggravate  myocardial function via down regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10), 10/June/2015,  9.43 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Undisclosed information: How AGEs decreases the expression of PNUTS/PPP1R10

Comments are closed.